search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
NEWS&VIEWS 21 Biopharmaceutical Expert Joins Sartorius


bioreactors, which is said to currently represent the most comprehensive range in the industry.


Most recently Christel was General Manager of Recipharm Biologics and previous posts included senior management positions in biopharmaceutical development at AstraZeneca. She has doctorate in Biochemistry from the University of Hanover, Germany.


Dr Christel Fenge


Dr Christel Fenge has joined the Sartorius Stedim Biotech group as Vice President of Marketing for Fermentation Technologies. She is globally responsible for managing the product portfolio of multi- and single-use


“We are extremely pleased to have Dr Fenge join our organisation to strengthen our Fermentation Technology activities, particularly with regard to implementing and supporting our single-use technology approach (in which) she will play an essential role,” explained Reinhard Vogt, Member of the Board of Sartorius Stedim Biotech. “She brings with her an exceptional experience base of cell culture and protein science, which will further our customer support and technology bases.”


TO FIND OUT MORE CIRCLE NO.


Memmert Invests in Location in Germany


Mrs Christiane Riefler-Karpa addresses guests at Memmert


Memmert, the Schwabach Germany–based manufacturer of ovens and climate chambers is putting into operation a new punching and bending line with a total investment of 3 million Euros.


According to Spectaris, the German professional association for analysis, biological and laboratory technology, the turnover of German companies in this sector fell by some 8% in the crisis year of 2009 compared to the year before. Countering this trend, Memmert was able to hold its turnover at about the same level. In August 2010,


growth figures are already in double digits compared to the previous year’s turnover, putting Memmert on a healthy growth course. During the official start-up of the new punching and bending line, managing director Christiane Riefler-Karpa made clear that the successful company policy of the past will be continued. “Instead of concentrating on volume and having to make compromises in quality and fittings as seen in our competitors, we will now be able to implement individual customer requests during production on absolutely competitive terms and, not least, in a very short time”


The investment was made in the new Salvagnini processing line for punching and bending sheet metal. With a total length of 36 metres, this is the largest and most modern installation of its kind in Europe, a source said. This project goes hand in hand with other large-scale investment projects already completed, such as a new appliance testing centre and represents a central factor in Memmert’s competitiveness. It secures 160 jobs in Germany, with increasingly optimistic employment prospects.


TO FIND OUT MORE CIRCLE NO. 69 67


RCUK Sources Oligonucleotides


Close to Home Sigma Life Science, a division of Sigma- Aldrich®


Corporation and a leading


European manufacturer of oligonucleotides, has signed a three-year contract with Research Councils UK (RCUK) Shared Services Centre Ltd to be a preferred supplier for synthetic oligonucleotides. With more than 20 years of experience in this field, Sigma Life Science has a UK production facility in Haverhill, near Cambridge.


Michael Harris, Managing Director of Europe, Middle East, Africa regions for Sigma-Aldrich, commented: “Sigma Life Science has been a preferred oligonucleotide supplier to the Medical Research Council (one of the UK’s seven Research Councils) for over four years, and we are delighted that the quality of our products and service has resulted in the expansion of this contract. This new agreement is expected to enable additional RCUK researchers to access Sigma’s products, as well as allow Sigma Life Science to consolidate its relationship with RCUK.”


TO FIND OUT MORE CIRCLE NO. 68


Quantachrome Completes Assets Acquisition


Quantachrome Instruments has completed the acquisition of certain assets of Wenman Scientific, a privately held company that provides capillary flow porometers for pore size measurements. Financial details were not disclosed. Wenman Scientific’s President, Richard Wenman, will immediately join Quantachrome Instruments in the capacity of Manager, Porometer Products. The combined technology and capabilities of these companies will allow Quantachrome to further expand it range of products and services by providing capillary flow porometers in business sectors as diverse as filtration, textiles, fuel cells, membranes, and coated papers. The acquisition allows for expanded marketing and support of these innovative porometer technologies via Quantachrome’s worldwide network of offices and distributors in over 50 countries.


TO FIND OUT MORE CIRCLE NO. 70


SP Scientific has signed a license agreement with Praxair, Inc, to utilise Praxair's ControLyo nucleation on-demand technology for control over the freeze-drying process for drug developmental efforts.


"With the combined strength of SP Scientific's leading line of laboratory lyophilisers and Praxair's ControLyo nucleation on-demand technology, drug manufacturers can consider a variety of formulations during drug and process development. ControLyo technology enables precise control of the lyophilisation process using one of the most advanced and innovative freeze- drying tools on the market today," said Rich Jarrett, Director of Business Development for Praxair's Biopharma business.


According to Bill Downs, SP Scientific's Chief Operating Officer and Executive Vice President, "Praxair's technology fits perfectly with our mission of offering customers the most technically advanced freeze-drying equipment and tools to improve their overall economics and processes. We are very excited about the combination of Praxair's technology and our advanced lyophilisers and tools used to help customers with their freeze-drying needs."


IDBS, a leading provider of research data management and analytics solutions to R&D organisations, has formed a new global unit dedicated to provision of healthcare and translational medicine-focused solutions.


German Federal Minister Visits WITec


The German Federal Minister of Education and Research Dr. Annette Schavan, recently discovered life on the micro-scale during a visit to WITec’s headquarters in Ulm. Looking at single molecules using the company’s nano-analytical imaging systems, Dr Schavan, said that she was impressed by the microscope technology:


“The share of research and innovation in value creation is in no other


industrial country as high as in Germany. For that reason companies like WITec represent the workshops for the future of our country.”


Dr Annette Schavan visits WITec’s headquarters in Ulm.


During her visit Schavan also learned about high-resolution optical and scanning probe microscopy and new developments or patents incorporated in the company’s modular product line. As a member of the bio-photonic research association Exprimage, which is supported by the German Science Ministry, WITec is involved in developing new tools for tumour diagnostics. “It is always nice to see who we are supporting with one’s own eyes. That is why I have very much enjoyed coming here”, said Schavan at the end of her visit.


TO FIND OUT MORE CIRCLE NO. 71


Neil Kipling, Founder and CEO of IDBS said that the move represented: “a natural evolution of our capabilities and builds on the knowledge and expertise gained from our years of work in research, preclinical and clinical areas with leading commercial, academic and healthcare groups, Our intention with the healthcare unit is twofold: First, we can capitalise on our proven leadership and in-depth knowledge of translational medicine to extend our solution to improve the understanding and use of healthcare data. Second, by creating a separate healthcare unit, we can maintain our fundamental emphasis on the enterprise platforms within pharmaceuticals and R&D organisations that are the foundation of IDBS.”


TO FIND OUT MORE CIRCLE NO. 72


Danaher Corporation and Keithley Instruments, Inc, have entered into a definitive merger (Sept) pursuant to which Danaher will acquire all of the outstanding Common Shares and Class B Common Shares of Keithley at a purchase price of $21.60 per share in cash for an enterprise value of approximately $300 million net of cash to be assumed. The acquisition has been unanimously approved by the Keithley Board of Directors.


Keithley Instruments, Inc


designs, develops, manufactures, and markets complex electronic instruments and systems; product offerings include integrated systems solutions, along with instruments and data acquisition modules that can be used as system components or stand-alone solutions. Upon closing Keithley will be part of Danaher’s Tektronix business


Corning Incorporated has completed the acquisition of all outstanding shares of Plaslab SAS from certain investment funds managed by Qualium Investissement and from other shareholders. Plaslab company Plastiques Gosselin, (Borre, France), a leading manufacturer and distributor of consumable labware in Europe, will be integrated into Corning’s Life Sciences segment and Jean Gosselin will remain as President of Plaslab and Plastiques Gosselin. The consumables lines will complement the general labware, cell culture, lab equipment, and HTS/Assay products offered by Corning. The acquisition also furthers Corning’s strategy to continue to improve balance by strengthening its Life Sciences segment.


READ ALL THE LATEST NEWS & VIEWS, ARTICLES AND NEW PRODUCT RELEASES ONLINE, VISIT: WWW.LABMATE-ONLINE.COM


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68